GlassScriptPhysician profile
Judy A Smith
NPI 1225114127
$9,038.57
in general payments reported to CMS, 2019-2025
42 companies · $1,422 in 2025
The $1,422 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,524 · 2022: $2,125 · 2023: $1,503 · 2024: $1,464 · 2025: $1,422.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,389.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,388.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,566.21 | 2021-2025 | |
| Collegium Pharmaceutical, INC. | $1,269.09 | 2021-2025 | Xtampza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $691.07 | 2021-2025 | Relistor |
| Scilex Pharmaceuticals INC. | $639.06 | 2021-2025 | Ztlido |
| Pfizer INC. | $572.24 | 2023-2025 | |
| Optinose US, INC. | $512.58 | 2022-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $438.47 | 2021-2024 | Trintellix |
| Amgen INC. | $335.04 | 2021-2025 | Krystexxa |
| Idorsia Pharmaceuticals US INC | $305.51 | 2022-2024 | Quviviq |
| Biohaven Pharmaceutical Holding Company LTD. | $259.51 | 2022 | |
| Eisai INC. | $248.58 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $217.20 | 2021-2022 | |
| Boston Scientific Corporation | $206.65 | 2024-2025 | Intracept Rf Probe, Wavewriter Alpha Prime 16, Intracept |
| Allergan, INC. | $196.59 | 2021-2022 | |
| Globus Medical, INC. | $195.33 | 2025 | Senza |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $195.17 | 2022-2023 | Belsomra |
| Upsher-Smith Laboratories LLC | $183.80 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $183.09 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $130.06 | 2021 | |
| Valinor Pharma, LLC | $80.40 | 2025 | Movantik |
| Nalu Medical, INC. | $79.67 | 2021-2025 | Nalu Neurostimulation System |
| Lilly USA, LLC | $78.13 | 2021-2022 | |
| Nevro Corp. | $48.81 | 2022-2024 | Senza |
| Ibsa Pharma INC. | $44.06 | 2023 | Tirosint, Licart |
| Novartis Pharmaceuticals Corporation | $30.66 | 2021 | |
| Protega Pharmaceutials INC | $28.17 | 2024 | Roxybond |
| Gilead Sciences, INC. | $27.19 | 2025 | |
| Relievant Medsystems, INC. | $24.10 | 2023 | Intracept |
| Redhill Biopharma INC. | $23.82 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $23.82 | 2024 | |
| Neurometrix INC | $23.02 | 2023 | |
| Vanda Pharmaceuticals INC. | $20.98 | 2025 | Fanapt |
| Atland Pharmaceuticals, LLC | $20.24 | 2025 | Tolmetin Sodium, Orphenadrine Citrate, Aspirin and Caffeine |
| Horizon Therapeutics Plc | $20.08 | 2023 | Krystexxa |
| Azurity Pharmaceuticals, INC. | $18.18 | 2025 | |
| Ultragenyx Pharmaceutical INC. | $17.41 | 2022 | |
| Averitas Pharma INC. | $16.20 | 2025 | Qutenza |
| Kowa Pharmaceuticals America, INC. | $14.39 | 2022 | |
| Uswm, LLC | $14.18 | 2021 | |
| Curonix LLC | $13.77 | 2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Pacira Pharmaceuticals Incorporated | $13.03 | 2021 | |
| Hikma Pharmaceuticals USA | $13.01 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Judy Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.